Bros. Advisors Lp Baker Sells 1,037,017 Shares of BeiGene, Ltd. (NASDAQ:BGNE) Stock

BeiGene, Ltd. (NASDAQ:BGNE) Director Bros. Advisors Lp Baker sold 1,037,017 shares of BeiGene stock in a transaction on Monday, December 9th. The shares were sold at an average price of $187.27, for a total value of $194,202,173.59. Following the sale, the director now directly owns 791,493 shares in the company, valued at $148,222,894.11. The trade was a 56.71 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

BeiGene Trading Down 9.7 %

Shares of BeiGene stock traded down $20.12 on Tuesday, reaching $187.50. 1,260,565 shares of the company were exchanged, compared to its average volume of 280,145. BeiGene, Ltd. has a fifty-two week low of $126.97 and a fifty-two week high of $248.16. The firm has a market capitalization of $18.27 billion, a price-to-earnings ratio of -22.75 and a beta of 0.57. The company has a current ratio of 1.93, a quick ratio of 1.72 and a debt-to-equity ratio of 0.05. The stock has a fifty day moving average price of $210.61 and a 200-day moving average price of $186.53.

BeiGene (NASDAQ:BGNE) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.04). BeiGene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $983.26 million. During the same quarter in the previous year, the firm posted $2.01 EPS. BeiGene’s quarterly revenue was up 28.2% on a year-over-year basis. On average, analysts expect that BeiGene, Ltd. will post -5.64 EPS for the current year.

Institutional Investors Weigh In On BeiGene

Hedge funds have recently made changes to their positions in the company. Blue Trust Inc. lifted its stake in BeiGene by 156.3% in the 3rd quarter. Blue Trust Inc. now owns 123 shares of the company’s stock worth $28,000 after acquiring an additional 75 shares in the last quarter. Allspring Global Investments Holdings LLC acquired a new position in shares of BeiGene in the 3rd quarter valued at about $36,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of BeiGene in the third quarter worth approximately $67,000. SG Americas Securities LLC purchased a new stake in shares of BeiGene in the third quarter worth approximately $105,000. Finally, PFG Investments LLC acquired a new stake in shares of BeiGene during the third quarter worth approximately $210,000. Hedge funds and other institutional investors own 48.55% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on BGNE. JMP Securities assumed coverage on shares of BeiGene in a research note on Wednesday, September 18th. They issued a “market outperform” rating and a $288.00 price target for the company. JPMorgan Chase & Co. upped their target price on BeiGene from $200.00 to $235.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 22nd. StockNews.com cut BeiGene from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. TD Cowen upped their price objective on BeiGene from $254.00 to $260.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $300.00 target price on shares of BeiGene in a report on Tuesday, December 3rd. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, BeiGene currently has an average rating of “Moderate Buy” and a consensus price target of $253.69.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.